Overview

Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.
Phase:
Phase 2
Details
Lead Sponsor:
Russian Academy of Medical Sciences
Treatments:
Eculizumab